Business
iFabric Corp Updates on Clinical Trial for Treated Medical Scrubs
MARKHAM, ON / ACCESSWIRE / July 21, 2022 / iFabric Corp. ("iFabric" or the "Company") (TSX:I...
About this update from Ifabric Corp.
[{"type":"text","content":"iFabric Corp Updates on Clinical Trial for Treated Medical ScrubsMARKHAM, ON / ACCESSWIRE / July 21, 2022 / iFabric Corp. (\"iFabric\" or the \"Company\") (TSX:IFA)(OTCQX:IFABF), today provides an update on its clinical trial of medical garments (i.e. \"scrubs\") treated with the Company's ProTX2 antimicrobial and REPELTX water-repellent technologies.\"I am pleased to report that phase one of our trial has now been completed,\" said Hylton Karon, President and CEO of iFabric.\"Our trial was conducted at MemorialCare Medical Group - Irvine, in the United States,\" added Mr. Karon.\"The trial comprised of scrubs supplied in three forms: One treated with our ProTX2 antimicrobial technology, another with a combination of ProTX2 and RepelTX (durable water-repellant technology), and a third (control) group of untreated scrubs. The trial comprised 125 nurses recruited for 3 shifts per nurse, equating to a total of 375 regular staff-shifts. At the start of each shift, nurses were provided new and unmarked scrubs from one of the three groups, which were swabbed twice, once prior to the commencement of the shift and a second time at the end of the shift. The principal endpoint of the trial is to compare bacterial loads on the scrubs treated with our technologies compared to the untreated scrubs. A pathogen load reduction is key to enhancing the protection of the wearer and those with which they encounter during their workday. The spread of infection from surface contact is a major concern in the healthcare industry.\"The trial now moves to it's second, laboratory-based phase, which involves testing for bacterial loads. Once all the laboratory testing is completed, the third step will be to analyze the data under a set of criteria established prior to the trial. The fourth and final step will be providing our analyses to a recognized medical journal for peer review and publishing. Further updates will be provided as the trial progresses through the remaining phases,\" concluded Hylton Karon.ABOUT ProTX2ProTX2® is a powerful eco-friendly technology that provides antibacterial, antimicrobial, antimold, anti-mildew and anti-odour protection. When treated, each textile fiber is fundamentally transformed through PROTX2®'s technology, providing proprietary unrivalled protection against pathogens associated with healthcare-associated in...